

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

**(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL
MEETING HELD ON 9 FEBRUARY 2026;
(2) CHANGE OF DIRECTORS AND
COMPOSITION OF BOARD COMMITTEES; AND
(3) CHANGE OF CHAIRMAN OF THE BOARD**

POLL RESULTS OF THE EGM

The Board is pleased to announce that all resolutions as set out in the Notice dated 23 January 2026 were duly passed by way of poll by the Shareholders at the EGM held on Monday, 9 February 2026.

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The Board also announces that as the appointment of Mr. Yang Peng, Dr. Gao Guangxia, Dr. Shen Sheng, Prof. Shen Zuojun and Dr. He Xin as the Directors expired at the EGM and all of them did not offer themselves for re-appointment as they would like to devote more time on their other commitments, (a) each of Mr. Yang Peng, Dr. Gao Guangxia, Dr. Shen Sheng ceased to be a non-executive Director; (b) Prof. Shen Zuojun ceased to be an independent non-executive Director, the chairman of the Remuneration Committee, a member of each of the Audit Committee and the Nomination Committee; and (c) Dr. He Xin ceased to be an independent non-executive Director, a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee, all with effect from 9 February 2026.

The Board further announces that Ms. Kang Rui has been appointed as a non-executive Director and Prof. Jin Tengchuan has been appointed as an independent non-executive Director, all with effect from 9 February 2026 following the approval of their appointments by the Shareholders at the EGM.

The Board further announces that following the completion of re-election for the ninth session of the Board at the conclusion of the EGM, there are changes to composition of the Board committees. The Audit Committee now comprises of Mr. Fan Xiaoliang (Chairman), Prof. Shen Jiangang and Prof. Jin Tengchuan. The Nomination Committee now comprises of Prof. Jin Tengchuan (Chairman), Mr. Fan Xiaoliang and Prof. Shen Jiangang. The Remuneration Committee now comprises of Prof. Shen Jiangang (Chairman), Mr. Fan Xiaoliang and Prof. Jin Tengchuan.

CHANGE OF CHAIRMAN OF THE BOARD

The Board is also pleased to announce that, with effect from 9 February 2026, Mr. Chen Peng, an executive Director and the President, has been appointed as the Chairman.

Following the appointment of Mr. Chen Peng as the Chairman, Mr. Chen Zhengyong ceased to be the Chairman with effect from 9 February 2026 but will remain as an executive Director.

References are made to the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) dated 23 January 2026 of Biosino Bio-Technology and Science Incorporation (the “**Company**”), and the circular (the “**Circular**”) of the Company dated 23 January 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM

The EGM was held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Monday, 9 February 2026. The Board is pleased to announce that all resolutions as set out in the Notice were duly passed at the EGM. As at the date of the EGM, the Company issued a total of 144,707,176 Shares, comprising 64,286,143 H Shares and 80,421,033 Domestic Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the EGM. There were no Shares entitling the holders thereof to attend and vote only against the resolutions at the EGM. No restriction was imposed on any Shareholder casting votes on any of the proposed resolutions at the EGM. All the resolutions at the EGM were put to the vote by way of poll. BDO China Shu Lun Pan Certified Public Accountants LLP was appointed as the scrutineer at the EGM for the purpose of vote-taking.

All Directors attended the EGM either in person or by electronic means.

The poll results of the respective resolutions at the EGM are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To consider and approve the appointments and re-appointments of the following directors of the Company (the “ Director(s) ”), and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:–		
(a)	To consider and approve the re-appointment of Mr. Chen Zhengyong as an executive Director;	102,116,122 (100%)**	0 (0%)**
(b)	To consider and approve the re-appointment of Mr. Li Zhonghua as an executive Director;	102,116,122 (100%)**	0 (0%)**
(c)	To consider and approve the re-appointment of Mr. Chen Peng as an executive Director;	102,116,122 (100%)**	0 (0%)**
(d)	To consider and approve the re-appointment of Prof. Shen Jiangang as an independent non-executive Director;	102,116,122 (100%)**	0 (0%)**
(e)	To consider and approve the re-appointment of Mr. Fan Xiaoliang as an independent non-executive Director;	102,116,122 (100%)**	0 (0%)**
(f)	To consider and approve the appointment of Ms. Kang Rui as a non-executive Director; and	102,116,122 (100%)**	0 (0%)**
(g)	To consider and approve the appointment of Prof. Jin Tengchuan as an independent non-executive Director.	102,116,122 (100%)**	0 (0%)**
SPECIAL RESOLUTIONS		For	Against
2.	To consider and approve the proposed amendment to the articles of association of the Company.	102,116,122 (100%)**	0 (0%)**
3.	To consider and approve the proposed amendment to the Rules of Procedure of the Board of Directors.	102,116,122 (100%)**	0 (0%)**

** The percentage of voting Shares is based on the total number of Shares held by the Shareholders who voted at the EGM in person or by proxy.

As more than 50% of the total number of Shares held by the Shareholders who voted at the EGM were cast in favour of each of the resolution nos. 1(a)-(g) and more than two-thirds of the total number of Shares held by the Shareholders who voted at the EGM were cast in favour of resolution nos. (2) and (3), all the above resolutions were approved by the Shareholders.

CHANGE OF DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The Board also announces that as the appointment of Mr. Yang Peng (“**Mr. Yang**”), Dr. Gao Guangxia (“**Dr. Gao**”), Dr. Shen Sheng (“**Dr. Shen**”), Prof. Shen Zuojun (“**Prof. Shen ZJ**”) and Dr. He Xin (“**Dr. He**”) as the Directors expired at the EGM and all of them did not offer themselves for re-appointment as they would like to devote more time on their other commitments, (a) each of Mr. Yang, Dr. Gao, Dr. Shen ceased to be a non-executive Director; (b) Prof. Shen ZJ ceased to be an independent non-executive Director, the chairman of the Remuneration Committee, a member of each of the Audit Committee and the Nomination Committee; and (c) Dr. He ceased to be an independent non-executive Director and a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee, all with effect from 9 February 2026.

Each of Mr. Yang, Dr. Gao, Dr. Shen, Prof. Shen ZJ and Dr. He has confirmed that he/she has no disagreement with the Board, and there are no matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its appreciation for the valuable contribution of Mr. Yang, Dr. Gao, Dr. Shen, Prof. Shen ZJ and Dr. He towards the Company during their tenure of service.

The Board further announces that Ms. Kang Rui (“**Ms. Kang**”) has been appointed as a non-executive Director and Prof. Jin Tengchuan (“**Prof. Jin**”) has been appointed as an independent non-executive Director, all with effect from 9 February 2026 following the approval of their appointments by the Shareholders at the EGM.

The Board further announces that following the completion of re-election for the ninth session of the Board at the conclusion of the EGM, there are changes to composition of the Board committees. The Audit Committee now comprises of Mr. Fan Xiaoliang (Chairman), Prof. Shen Jiangang and Prof. Jin Tengchuan. The Nomination Committee now comprises of Prof. Jin Tengchuan (Chairman), Mr. Fan Xiaoliang and Prof. Shen Jiangang. The Remuneration Committee now comprises of Prof. Shen Jiangang (Chairman), Mr. Fan Xiaoliang and Prof. Jin Tengchuan.

Biographical details of Ms. Kang and Prof. Jin are as follows:

Ms. KANG Rui (康睿女士), aged 25, obtained a bachelor’s degree in Broadcasting and Hosting Arts from Shandong Youth University of Political Science in June 2022. Since February 2023, Ms. Kang has been employed by Boke Holdings Group Co., Ltd.* (博科控股集團有限公司), where she currently serves as an administrative manager and is primarily responsible for the establishment of institutional systems, planning of large-scale events, and internal administrative management. Ms. Kang is also a director of Shandong Biobase Zhongsheng Technology Co., Ltd.* (山東博科中生科技有限公司), a substantial Shareholder.

The Company will enter into a service agreement with Ms. Kang and her term of service with the Company will end at the expiration of the term of the current session of the Board. Her remuneration will be determined by the Board and the Remuneration Committee with reference to her duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Ms. Kang did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

There are no other matters relating to the appointment of Ms. Kang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Prof. Jin Tengchuan (金騰川教授), aged 45, obtained dual bachelor's degrees in biophysics and business administration from University of Science and Technology of China in 2003. He also obtained a doctoral degree in biochemistry and molecular biology from Illinois Institute of Technology in the United States in 2008. From 2008 to 2014, he served successively as Postdoctoral Fellow and Research Fellow at the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) in the United States. In 2015, he was appointed as Specially Appointed Researcher and PhD Supervisor at the School of Life Sciences, University of Science and Technology of China, and was promoted to Professor in 2021. He has published in journals including Immunity, Cell Research, Journal of Experimental Medicine, Nature Communications, Signal Transduction and Targeted Therapy, Nucleic Acids Research, Cell Discovery, Protein & Cell, Cellular & Molecular Immunology, and Cell Reports. Since 2025, he has served as Executive Editor-in-Chief of iNew Medicine and as an editorial board member of Allergy Medicine and Bulletin of Obstetrics & Gynecology.

The Company will enter into a service agreement with Prof. Jin and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Prof. Jin did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

Prof. Jin has confirmed (i) his independence as regards to each of the factors referred to in Rule 5.09(1) to (8) of the GEM Listing Rules; (ii) that he has no past or present financial or other interests in the business of the Group, nor is he connected with any core connected person (as defined in the GEM Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment.

There are no other matters relating to the appointment of Prof. Jin that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board wishes to take this opportunity to welcome Ms. Kang and Prof. Jin for joining the Board.

CHANGE OF CHAIRMAN OF THE BOARD

The Board is also pleased to announce that, with effect from 9 February 2026, Mr. Chen Peng, an executive Director and the president of the Company (the “**President**”), has been appointed as chairman of the Board (the “**Chairman**”).

Biographical details of Mr. Chen Peng are as follows:

Mr. CHEN Peng (陳鵬先生), aged 50, is an executive Director, the Chairman and the President. Mr. Chen Peng joined the Company in December 2021. He graduated from Anhui University of Chinese Medicine (安徽中醫學院) with a bachelor’s degree in Integrated Chinese and Western Medicine (中西醫結合臨床專業) in 1998, and obtained a master of business administration degree from Fairfield University in the United States. He served as the technical director of Shanghai Fosun High Technology (Group) Co., Ltd.* (上海複星高科技(集團)有限公司) and the chairman and president of Anhui Meikang Hospital Investment Management Co., Ltd. (安徽美康醫院投資管理股份有限公司). He is currently serving as an executive director of Beijing Zhongsheng Technology Achievement Transformation Center Co., Ltd.* (北京中生科技成果轉化中心有限公司), the chairman of Biosino (Suzhou) Medical Technology Co., Ltd.* (中生(蘇州)醫療科技有限公司) and the chairman of Guoke Health Hospital Industry Group* (國科健康院產業集團).

The Company has not entered into any service contract/letter of appointment with Mr. Chen Peng in relation to his appointment as the Chairman. His term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, Jingning Guoke Kangyi Enterprise Management Center LLP* (景寧國科康儀企業管理中心(有限合夥)) (“**Jingning**”) owned 11,330,334 Domestic Shares and Mr. Chen Peng owns 99.5% of equity interests in Jingning. Accordingly, he is deemed to be interested in the 11,330,334 Domestic Shares owned by Jingning.

Save as disclosed above, as at the date of this announcement, Mr. Chen Peng did not (i) hold any other positions in the Company or any of its subsidiaries; (ii) hold any directorship in any public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the past three years nor did he have other major appointments and professional qualifications; (iii) have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) have any interest in Shares within the meaning of Part XV of the SFO.

There are no other matters relating to the appointment of Mr. Chen Peng that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Following the appointment of Mr. Chen Peng as the Chairman, Mr. Chen Zhengyong ceased to be the Chairman with effect from 9 February 2026 but will remain as an executive Director.

Deviation from the Corporate Governance Code

As Mr. Chen Peng serves as both the Chairman and the President with effect from 9 February 2026, such practice deviates from code provision C.2.1 of the Corporate Governance Code as set forth in Appendix C1 of the GEM Listing Rules (the “CG Code”). The Board believes that vesting the roles of both the Chairman and the President in the same person can facilitate the execution of the Group’s business strategies and boost effectiveness of its operation. Therefore, the Board considers that the deviation from the code provision C.2.1 of the CG Code is appropriate in such circumstance. In addition, the Board, which comprises three executive Directors, one non-executive Director and three independent non-executive Directors, is appropriately structured with the balance of power to provide sufficient checks to protect the interests of the Company and the Shareholders.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, the PRC, 9 February 2026

As at the date of this announcement, the Board comprises:

Chairman, President and executive Director

Mr. Chen Peng (陳鵬先生)

Vice chairman and executive Director

Mr. Li Zhonghua (李忠華先生)

Executive Director

Mr. Chen Zhengyong (陳正永先生)

Non-executive Director

Ms. KANG Rui (康睿女士)

Independent non-executive Directors

Prof. Jin Tengchuan (金騰川教授), Prof. Shen Jiangang (沈劍剛教授) and Mr. Fan Xiaoliang (范曉亮先生)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.